



Universiteit
Leiden

The Netherlands

Fetal and neonatal alloimmune thrombocytopenia: the proof of the pudding is in the eating

Vos, T.W. de

Citation


Vos, T. W. de. (2023, April 13). *Fetal and neonatal alloimmune thrombocytopenia: the proof of the pudding is in the eating*. Retrieved from <https://hdl.handle.net/1887/3593976>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3593976>

Note: To cite this publication please use the final published version (if applicable).



CHAPTER 8

Long-term neurodevelopmental outcome in children after antenatal intravenous immunoglobulin treatment in fetal and neonatal alloimmune thrombocytopenia

Thijs W. de Vos
Masja de Haas
Dick Oepkes
Ratna N.G.B. Tan
C. Ellen van der Schoot
Sylke J. Steggerda
Linda S. de Vries
Enrico Lopriore
Jeanine M.M. van Klink

ABSTRACT

BACKGROUND

Children with fetal and neonatal alloimmune thrombocytopenia (FNAIT) face increased risk of intracranial hemorrhage (ICH) potentially leading to developmental impairment. To prevent ICH, pregnant women with alloantibodies against fetal platelets are often treated with intravenous immunoglobulin (IVIg). IVIg appears effective in vastly reducing the risk of fetal or neonatal bleeding complications. However, information on long-term neurodevelopment of these children is lacking.

OBJECTIVE

To evaluate long-term neurodevelopmental outcome in children with FNAIT who were treated with IVIg antenatally.

STUDY DESIGN

An observational cohort study was performed including children of mothers who were treated with IVIg during pregnancy because a previous child was diagnosed with FNAIT. Children were invited for a follow-up assessment including standardized cognitive and neurologic tests. The parents were asked to complete a behavioral questionnaire and school performance reports. The primary outcome was severe neurodevelopmental impairment (NDI), defined as severe cognitive impairment (IQ < 70), cerebral palsy with Gross Motor Function Classification System (GMFCS) Level ≥ 3 , bilateral blindness, and/or bilateral deafness (requiring amplification). The secondary outcome was mild to moderate NDI, defined as either mild to moderate cognitive impairment (IQ < 85), cerebral palsy with GMFCS Level ≤ 2 , minor neurologic dysfunction, vision loss, and/or hearing loss.

RESULTS

Between 2003 and 2017, 51 children were liveborn after antenatal IVIg treatment. One family moved abroad and was therefore not eligible for inclusion. In total, 82% (41/50) of the eligible cases were included for neurodevelopmental assessment at a median age of 9 years and 8 months. Severe NDI was not detected. The incidence of mild to moderate NDI was 14% (6/41, 95% confidence interval: 6%–29%). The children's mean cognitive score, behavioral scores, and academic achievement were not different from the Dutch norm groups. Neuroimaging was performed in 90% (37/41) of cases. Severe ICH had been diagnosed in two cases (5%), one antenatally before the start of IVIg and the other case 1 day after birth. Both cases had a normal neurodevelopmental outcome.

CONCLUSION

The risk of NDI in children whose mothers were treated for FNAIT with antenatal IVIg is comparable to that in the general population

AJOG AT A GLANCE

Why was the study conducted?

In fetal and neonatal alloimmune thrombocytopenia (FNAIT), administration of intravenous immune globulin (IVIg) to the mother during pregnancy is widely accepted for preventing the occurrence of antenatal or perinatal intracranial hemorrhage (ICH) in the child. However, knowledge about the long-term neurodevelopmental outcome of these children is lacking.

What are the key findings?

Mild to moderate neurodevelopmental impairment was present in 6/41 (14%) children. Two children were diagnosed with severe ICH. Both had normal neurodevelopmental outcomes.

What does the study add to what is already known?

Neurodevelopmental outcome of children with FNAIT that were born after a pregnancy in which their mother was treated with IVIg is comparable to that in the general population.

INTRODUCTION

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a disease defined by maternal human platelet antigen (HPA)-directed alloantibodies. The maternal antibodies can induce severe thrombocytopenia and possibly damage the endothelial cell layer with an increased risk of fetal or neonatal intracranial hemorrhage (ICH), potentially leading to irreversible brain damage or perinatal death.¹⁻³ The recurrence rate of ICH in subsequent HPA-incompatible pregnancies is up to 72%.⁴ The mainstay of antenatal treatment of FNAIT to reduce the bleeding risk in the unborn child is weekly administration of intravenous immunoglobulin (IVIg) to the pregnant woman.^{5,6} In the absence of a screening program, this treatment is almost exclusively given to women who had a previous pregnancy complicated by FNAIT.⁷ The exact mechanism of maternal IVIg treatment is not completely understood. It is hypothesized that IVIg treatment leads to lower pathogenic IgG transport from mother to fetus.^{8,9}

Although virtually every guideline worldwide recommends IVIg treatment, the use of IVIg during pregnancy is currently still off-label.⁶ The efficacy on reduction of the risk of ICH appears to be very high,⁵ although no placebo-controlled studies have been done. The lack of understanding of the mechanism of action of IVIg, raises some concerns about its widespread use and safety in FNAIT. Adverse maternal effects of IVIg include but are not limited to, headache, rash, fatigue, hemolytic anemia, renal failure, pancytopenia and aseptic meningitis.^{10,11} Whether IVIg may also have adverse effects in fetuses, including long-term side effects and neurodevelopmental impairment, is not well known.

Currently, only two small cohort studies have assessed the long-term neurodevelopmental outcomes of children with FNAIT after antenatal treatment.^{12, 13} These studies concluded that long-term outcomes of these children were favorable. However, the interpretation of the studies was hampered by methodological limitations: substantial loss to follow-up, remote developmental assessment, and heterogeneous study population.^{12,13} Knowledge of long-term outcomes is essential to evaluate and improve the current quality of care and in evidence-based counselling of parents, particularly because children with FNAIT are at risk for ICH and its associated neurological sequelae. FNAIT survivors have a 70-82% risk of life-long sequelae (e.g., delayed development, cerebral palsy, cortical blindness, or seizures) as a result of the ICH.^{14,15}

This study aims to assess long-term neurodevelopmental outcome in children with FNAIT who were treated with IVIg during pregnancy. In addition, we assessed behavioral difficulties and school performance reports.

MATERIALS AND METHODS

STUDY POPULATION

Leiden University Medical Center (LUMC) is the national clinical expertise center in the Netherlands for platelet alloimmunization in pregnancy. Children of mothers referred to LUMC between 2003 and 2017 and who were treated with IVIg because of a risk of FNAIT were eligible for this study. FNAIT was diagnosed if there was a clinical suspicion in a previous pregnancy [neonatal platelet count $< 150 \times 10^9/L$ and/or (fetal) ICH or organ bleeding], confirmed fetal-maternal HPA incompatibility, and presence of HPA-directed antibodies in the maternal plasma.¹⁶ Exclusion criteria for long-term follow-up examination were severe congenital abnormalities unrelated to FNAIT or if the family moved abroad. Weekly maternal IVIg treatment was administered according to the clinical guidelines: 0.5 g/kg/week from 28 weeks of gestation in standard-risk pregnancies (without history of ICH or organ bleeding) and 1.0 g/kg/week starting between 16 and 20 weeks gestation in high-risk pregnancies (with a history of ICH or organ bleeding).⁷ Cesarean section was not recommended as standard delivery mode in HPA immunized pregnancies. For standard-risk pregnancies with a previous vaginal delivery, planned induction of labor was considered to be safe. Between January 2005 and September 2007 treatment was given according to the study protocol of a randomized trial in standard-risk pregnancies comparing low-dose IVIg (0.5 g/kg/week) with standard-dose IVIg (1.0 g/kg/week) starting at 28 weeks of gestation.¹⁷

ETHICS

The medical ethical committee of Leiden-Delft-Den Haag provided ethical approval (P19.069). All parents and children (aged ≥ 12 years) gave written informed consent. This study was registered at ClinicalTrials.gov (identifier: NCT04529382).

CLINICAL DATA

The following obstetric data were obtained from medical records: gravidity, parity, antenatal treatment, mode of delivery, specificity of the HPA alloantibody, and gestational age at delivery. Data on the occurrence of ICH or organ bleeding in previous children was also noted. The following neonatal data were obtained: platelet count nadir, postnatal treatment and bleeding symptoms, birth weight, sex, and neonatal morbidity. Two experienced neonatologists specialized in neonatal neurology (SS and LV) reviewed cerebral imaging and cerebral imaging reports. Severe ICH was defined as intraventricular hemorrhage (IVH) grade III or IV or ICH with parenchymal involvement visible on cranial ultrasound. Minor ICH was defined as IVH grade I or II.¹⁸ Severe organ bleeding was defined as organ bleeding requiring supportive care (e.g., ventilation in case of a pulmonary bleed). Neonatal morbidity was defined as the presence of one of the following conditions: perinatal asphyxia (5-min Apgar score < 7 or arterial cord blood pH < 7.0), neonatal sepsis (clinical suspicion of infection and positive blood culture), or necrotizing enterocolitis (NEC).¹⁹ Small for gestational age

(SGA) was defined as birthweight below the 10th percentile.²⁰ Maternal education levels were obtained from a demographic questionnaire and categorized according to the Dutch Social and Cultural Planning Office (in Dutch: Sociaal Cultureel Planbureau).²¹ All data were collected in a secure online database.²²

PROCEDURES

We first sent introduction letters to the parents, explaining the purpose of the study followed by a phone call. If informed consent was obtained, an appointment for follow-up assessment either at home or at our outpatient clinic was made. Neurodevelopmental assessment consisted of a standardized cognitive test and neurological examination. Parents were requested to complete a questionnaire on their child's behavior and to obtain school performance scores from their child's teachers.

Cognitive development in children aged 3–6 years was assessed using the Dutch version of the Wechsler Preschool and Primary Scale of Intelligence, 4th edition (WPPSI-IV-NL).²³ Cognitive development in children between 7 and 17 years of age was assessed using the Dutch version of the Wechsler Intelligence Scale for Children, 5th edition (WISC-V-NL).²⁴

Neurological functioning was examined with the adapted version of the Touwen examination for evaluating minor neurological dysfunction (MND).²⁵ This examination is divided into the following domains: posture, reflexes, involuntary movements, coordination, fine manipulative ability, associated movements, sensory deficits, and cranial nerve function. With one dysfunctional domain, outcome is classified as simple MND. If ≥ 2 clusters are dysfunctional, the outcome is classified as complex MND. The presence and grade of cerebral palsy (CP) was determined using the Gross Motor Function Classification System (GMFCS).²⁶

To investigate behavioral problems, parents completed the Child Behavior Checklist for 1.5–5 years or 6–18 years.²⁷ Standard T scores were created using a Dutch normative sample. These scores compare the raw score to what would be “normal” responses for children of the same age and gender. The T scores of the normative sample are scaled with a mean of 50 and an SD of 10. Higher scores indicate a greater severity of problems. For each broadband scale of internalizing, externalizing, and total behavior problems, T scores can be interpreted as on the borderline ($T = 60\text{--}63$, 84th–90th percentile) or in the clinical range ($T \geq 64$, $\geq 91^{\text{st}}$ percentile).

For children > 6 years, school performance reports were obtained from the Dutch National Pupil Monitoring System (Cito) for the following categories: reading comprehension, spelling and arithmetic/mathematics.²⁸ Individual scores were compared with age-matched peers and categorized into levels, I to V, with level I being the top 20% scoring children and level V being the lowest 20% scoring children.

OUTCOMES

The primary outcome was the incidence of severe neurodevelopmental impairment (NDI). NDI is a composite outcome consisting of four different domains: cognitive functioning, vision, hearing, and neurologic functioning. Severe NDI was defined as the presence of one of the following criteria: severe cognitive impairment (IQ < 70 [-2 SD]), CP GMFCS level \geq 3, bilateral blindness, and/or bilateral deafness (requiring amplification).²⁶ The secondary outcome was mild to moderate NDI, defined as the presence of one of the following criteria: mild to moderate cognitive impairment (IQ < 85 [-1 SD]), CP GMFCS level 1 or 2, MND, vision loss, or hearing loss.²⁶ Other outcomes were cognitive test scores (IQ) compared with Dutch norm scores and overall adverse outcome including severe NDI and/or perinatal mortality. In addition, we report the incidence of simple and complex MND, borderline and clinical behavior problems, and school performance scores.

STATISTICAL ANALYSES

Descriptive results are presented as the number of cases with percentages, mean with SD, or median with interquartile range (IQR) depending on the data type and distribution. Proportions of outcomes are presented with 95% confidence intervals (95% CI). The mean IQ scores were compared to Dutch norm data with a one-sample T test. The presence of behavioral problems and school performance scores were compared with the Dutch norm data using binomial tests. Data were analyzed using IBM SPSS Statistics software 26.0 (Chicago, IL, USA). Images were created with Microsoft Visio (Redmond, WA, USA). To examine selection bias, we compared the clinical characteristics of the included cases and the cases that were lost to follow-up.

RESULTS

STUDY POPULATION

Figure 1 shows the study population. One pregnancy complicated by HPA antibodies ended in fetal demise unrelated to FNAIT at 17 weeks of gestation. Autopsy revealed no signs of bleeding. Informed consent was obtained in 82% (41/50) of the eligible cases. Table 1 shows the characteristics of the included children (41 cases). In 12% (5/41) there was a history of severe ICH or organ bleeding in a previous pregnancy—three siblings were diagnosed with severe ICH, one with pulmonary bleeding and one with severe gastrointestinal bleeding. Clinical characteristics at birth of the included cases were comparable to those of children that were lost to follow-up (Supplemental Table). In 75% (30/40) of cases, the pregnant woman received standard-dose IVIg (0.5 g/kg/week) and in 25% (10/40) of the cases high-dosage IVIg (1 g/kg/week); in one case, the dose was not reported. None of the pregnant women were treated with corticosteroids. Fetal blood sampling was not performed. In total, 34% (14/41) of the children were delivered by cesarean section, in one case because of suspected placental

abruption at 31 weeks of gestation. The median gestational age at delivery was 37 weeks and 5 days with median birthweight of 3280 g. No neonatal morbidities occurred. The median platelet count nadir at birth was $65 \times 10^9/L$ (minimum $6 \times 10^9/L$; maximum $382 \times 10^9/L$). In 14 cases (34%), the nadir was $< 25 \times 10^9/L$ and in 18 cases (43%) the nadir was $< 50 \times 10^9/L$.




FIGURE 1. Flowchart of the study population

TABLE 1. Clinical and demographic characteristics of the FNAIT cases

Variable	n = 41
Diagnostics	
HPA specificity, n (%)	
HPA-1a	33 (80)
HPA-5b	4 (10)
Other	4 (10)
Pregnancy	
First pregnancy, n (%)	0
Severe hemorrhage in previous pregnancy, n (%)	5 (12)
Signs of fetal bleeding on ultrasound, n (%)	1 (2)
Maternal IVIg treatment, n (%)	41 (100)
Neonatal	
Gestational age at delivery, weeks+days, median (IQR)	37+5 (37+2 – 38+3)
Female sex, n (%)	21 (51)
Birthweight, gram, median (IQR)	3210 (2838 – 3427)
SGA (birthweight < 10th percentile), n (%)	2 (5)
Skin bleeding, n (%)	10 (24)
Intracranial hemorrhage, n/N (%)*	3/37 (8)
Minor: IVH grade I – II	1/37 (3)
Severe: Parenchymal	2/37 (5)
Platelet count nadir $\times 10^9/L$, median (IQR)	65 (20 – 161)
Platelet count < $25 \times 10^9/L$, n (%)	14 (34)
Postnatal treatment given, n (%)	14 (34)
Demographics	
Maternal education, n (%)	
Primary and secondary school	3 (7)
Intermediate vocational education	13 (32)
High vocational education or university	25 (61)

*Neuroimaging was not performed in 4/41 (10%) of the cases

Abbreviations: HPA, human platelet antigen; SGA, small for gestational age; IVH, intraventricular hemorrhage; L, liter; PTx, platelet transfusion; IVIg, intravenous immunoglobulin.

NEUROIMAGING

Postnatal neuroimaging was performed in 90% (37/41) of the cases. Cranial ultrasound was performed in 92% (34/37) of these cases and 8% (3/37) underwent both cranial ultrasound and magnetic resonance imaging (MRI). Two infants (3%, 2/37) were diagnosed with severe ICH. In one such infant, parenchymal bleeding was detected on fetal ultrasound 1 week before the planned start of IVIg treatment at 27 weeks of gestation. Antenatal treatment (high-dose) was started directly and the bleeding remained stable on ultrasound. At 36 weeks of gestation a cesarean section was performed. Postnatally, the bleeding was classified as severe ICH. In the second case with severe ICH, a round intraparenchymal lesion in the left frontal lobe was detected on neonatal ultrasound. This lesion was suspect for intraparenchymal hemorrhage and therefore classified as severe ICH. The postnatal platelet count of this infant was $382 \times 10^9/L$. Neonatal MRI was not performed. A previous child in this family had severe gastrointestinal bleeding due to FNAIT. Besides this family in which the

mother delivered an infant with ICH after the previous child had a severe gastrointestinal bleeding, severe bleeding did not reoccur in other pregnancies. In addition to the two cases of severe ICH, minor ICH was diagnosed in one child (3%, 1/37); IVH grade II was suspected on cranial ultrasound and confirmed with MRI.

LONG-TERM NEURODEVELOPMENTAL OUTCOMES

Table 2 shows the long-term neurodevelopmental outcomes of 41 children at a median age of 9 years and 8 months (minimum: 4 years 5 months; maximum 16 years 2 months). Forty children underwent cognitive assessment. Six children (15%, 6/40) were tested using the WPPSI-IV-NL; the mean IQ score in this group was 106 (SD 6). Thirty-four children (85%, 34/40) were tested using the WISC-V-NL; the mean IQ score in this group was 103 (SD 11). The mean full IQ score of the total cohort was 104 (SD 11), higher than their Dutch peers ($P = 0.042$, mean difference: 3.6). Three children had mild to moderate cognitive impairment (IQ score 70-85). The neurological examination of the children showed that, simple MND was present in 10% (4/40) of the children. Severe NDI was not detected, nor was perinatal mortality. The incidence of mild to moderate NDI was 14% (6/41, 95% CI: 5.6%–29%). Table 3 shows the details of the cases with mild to moderate NDI. All three cases with ICH (two severe and one mild) had normal neurodevelopment.

BEHAVIORAL FUNCTIONING AND SCHOOL PERFORMANCE

The internalizing scores, externalizing scores, and total behavior scores of the included children were comparable to Dutch norm data. School performance scores were available for 85% (35/41) of the children; six children were <6 years-old. One child in our study population required special-needs education, this child had mild-to-moderate NDI. Compared with the Dutch norm population, fewer children scored in our cohort in the lowest (level V) range for reading comprehension [6% (2/35) vs. 20%; $P = 0.019$] and mathematics [3% (1/35) vs. 20%; $P < 0.001$]. Nine percent (3/35) of the children scored in the lowest range (level V) for spelling.

TABLE 2. Neurodevelopmental outcome of antenatally treated FNAIT cases

Variable	n = 41
Age, years months, median (IQR)	9y8m (7y5m – 11y8m)
Cognitive	
Full IQ scale, mean (\pm SD)*	104 (11)
Verbal comprehension	106 (14)
Visual spatial score	103 (12)
Fluid reasoning scale	102 (12)
Working memory score	99 (12)
Processing speed	103 (16)
Normal range (TIQ > 85), n (%) [§]	38 (93)
Mild-moderate impairment (TIQ 85 – 70)	3 (7)
Severe cognitive impairment (TIQ < 70)	0
Neurological	
Minor Neurologic Dysfunction, n/N (%)*	
Simple MND	4/40 (10)
Complex MND	0
Abnormal domain, n/N (%)	
Posture	1/40 (3)
Reflexes	2/40 (5)
Involuntary movements	2/40 (5)
Coordination	2/40 (5)
Fine manipulative ability	0
Associated movements	1/40 (3)
Sensory deficits	1/40 (3)
Cranial nerve function	1/40 (3)
Cerebral Palsy, n (%)	0
Bilateral blindness or deafness	0
Behavior	
Total behavior problems (borderline to clinical), n (%)	2 (2)
Internalizing behavior problems (borderline to clinical), n (%)	3 (7)
Externalizing behavior problems (borderline to clinical), n (%)	2 (5)
NDI	
Neurodevelopmental impairment (NDI), n (%)	
Normal	35 (85)
Mild-moderate NDI	6 (15)
Severe NDI	0

*Cognitive test was not done in 1/41 (2%) anticipated FNAIT case.

[§]Based on the information of the school results and questionnaires that were completed by the caregivers case with missing cognitive test scores as normal.

*Neurological test was not completed in 1/41 (2%) anticipated FNAIT case.

Abbreviations: IQ, intelligence quotient; MND, minor neurologic dysfunction; GMFSC, Gross Motor Function Classification Score.

TABLE 3. Characteristics of cases with mild-moderate neurodevelopmental impairment

Sex	GA at birth (weeks)	SGA	Platelet count < 25×10 ⁹ /L	Neuroimaging (cranial ultrasound)	HPA	Age at evaluation (years)	TIQ	Neurological examination; abnormal domain	Behavior total problem score (CBCL)	School
Male	34	Yes	Yes	No abnormalities	HPA-1a	9	73	Simple MND; Sensory	Normal	Special needs education
Female	37	No	No	No abnormalities	HPA-1a	10	78	Normal	Normal	Regular education
Female	37	No	No	No abnormalities	HPA-1a	9	84	Normal	Normal	Regular education
Male	38	No	No	Not available	HPA-1a	8	89	Simple MND; Coordination	Normal	Regular education
Male	38	No	No	No abnormalities	HPA-1a	9	112	Simple MND; Coordination	Normal	Regular education
Female	37	No	No	No abnormalities	HPA-15a	10	112	Simple MND; posture	Normal	Regular education

Abbreviations: GA, gestational age; SGA, small for gestational age; G, gravidity; P, parity; L, liter; HPA, human platelet antigen; IQ, intelligence quotient; CBCL, Child Behavioral Checklist; MND, minor neurologic dysfunction; IVH, intraventricular hemorrhage.

COMMENT

PRINCIPAL FINDINGS

This is the first study to use standardized psychometric tests to assess the long-term neurodevelopmental outcomes of children whose alloimmunized mothers were treated with IVIg for FNAIT. Of the 41 children included, none had severe NDI. Mild to moderate NDI was diagnosed in three cases (7%) due to mild to moderate cognitive impairment. Simple MND was detected in 10% of the cases. All cases with ICH had normal neurodevelopmental outcomes. Behavior problem scores were within the normal range. Compared to Dutch norm scores for academic achievement, fewer children in our cohort scored at the lowest level for mathematics and reading comprehension.

RESULTS IN THE CONTEXT OF WHAT IS KNOWN

To date, only two cohort studies reported the long-term neurodevelopmental outcome of children born after antenatal FNAIT treatment. Ward *et al.*¹³ suggested better neurodevelopmental outcomes in 71 children after antenatal treatment compared with 71 untreated siblings. However, the investigators performed telephone-surveys only and their conclusions were hampered by a substantial (37%) lost-to follow up rate. Another study evaluated the neurodevelopmental outcome in 37 children born with FNAIT after antenatal treatment. Neurodevelopmental outcome of these children was found to be similar to that in the normal population.¹² An important limitation of this study was the large heterogeneity in fetal management strategies, including intrauterine platelet transfusion, IVIg treatment, or both. Our lost-to-follow-up rate was low, and we avoided the important limitations of these two studies by studying a cohort that received similar antenatal treatment, and by performing standardized neurodevelopmental tests in all participants. Compared with the general Dutch population, our study cohort had higher cognitive test scores. However, the mean difference of 3.6 IQ points is not clinically relevant, as this difference is less than +0.5 SD (7 IQ points) compared to the national average.¹⁷ The relatively high proportion of mothers with a high education level (61% vs. 41% in the Dutch general population) could explain the slightly higher IQ scores in our cohort.¹⁴ The rate of simple MND (4/40; 10%) was comparable to the rates in the literature in a healthy population, with 10% at pre-school age and up to 15% at school age (9-years-old).²⁹

An intriguing finding, in contrast to literature²², was the absence of NDI in the three children who were diagnosed with ICH as a fetus or neonate. The most severe ICH occurred before IVIg treatment was started, at 27 weeks of gestation. In our current protocol, the standard-risk pregnancies start treatment with IVIg at 24 weeks. The other two children had milder forms of bleeding, possibly even unrelated to FNAIT. Whether the IVIg may have had a protective effect on the vascular endothelium, as suggested by some recent studies, cannot be concluded from our data.¹⁻³

Despite weekly IVIg infusion, around forty percent of the children were born with a platelet count $< 50 \times 10^9/L$. This was in line with previous retrospective studies that reported that up to 67% of neonates had a platelet count $< 50 \times 10^9/L$ after IVIg treated pregnancies.⁵ These cases with severe thrombocytopenia despite antenatal IVIg treatment are sometimes referred to as ‘non-responders,’ while some colleagues suggest that this occurs because the dose of IVIg was too low in these cases.³⁰ The current study was not designed to provide explanations for this phenomenon.

CLINICAL IMPLICATIONS

This study used standardized tests to address the long-term neurodevelopmental outcome of children treated antenatally for FNAIT. It shows that the risk of severe NDI in this population is low. An earlier cohort^{14,15} study performed by our group reported severe and mild to moderate NDI in 60% and 10% of survivors with severe ICH due to untreated FNAIT, respectively.²² These findings are in line with another study reporting neurological sequelae in 82% of surviving FNAIT cases with ICH.²⁸ Both studies underline the importance of preventing ICH in pregnancies complicated by FNAIT. Currently, FNAIT is predominantly diagnosed in cases with thrombocytopenia as a chance finding or in cases with unexpected fetal/neonatal bleeding. In subsequent pregnancies, antenatal IVIg therapy appears to work exceptionally well, although adequate placebo- controlled studies are lacking. To prevent all ICH and its associated neurodevelopmental injury it would be necessary to timely start IVIg treatment in those pregnancies at risk for FNAIT with a high risk of severe neonatal outcome. Perhaps this would be possible with a long-debated population-based screening program. However, the efficacy of IVIg in such a cohort of first immunizations has not been studied; this would require setting up a screening program first. In addition to evaluating the long-term outcomes of children that were treated with IVIg, it would be interesting to assess the outcomes of children newly diagnosed with FNAIT. A study from our research group on the long-term outcomes of children with newly diagnosed FNAIT both with and without ICH is in preparation.

8

As well as FNAIT, antenatal IVIg treatment is indicated for several other diseases such as for example, hemolytic disease of the fetus and neonate, gestational alloimmune liver disease, antiphospholipid syndrome, and immune thrombocytopenia.³¹ Because of major differences in the pathophysiology of FNAIT and these other diseases it is not possible to generalize the favorable long-term outcomes of our study population to pregnancies with these conditions. However, the results from our study indicate that administration of IVIg during pregnancy did not have a negative impact on the cognitive, neurological and behavioral development of the children studied.

STRENGTHS AND LIMITATIONS

The major strength of our study is that all children underwent standardized assessment of cognitive, neurological, and behavioral development, including school performance scores,

which provides an integrated view of these children's neurodevelopmental outcomes. This cohort is the largest FNAIT cohort with antenatal IVIg treatment that has been assessed using standardized tests.

One limitation of this study is that we were unable to include all children in our follow-up (18% of the cases were lost to follow-up). However, our analysis showed that the clinical characteristics of the lost-to-follow-up group were similar to those of the children included in our study.

CONCLUSION

Normal distribution in cognitive, neurological, and behavioral development and school performance can be expected in children whose mothers have been treated with IVIg for FNAIT during pregnancy.

ACKNOWLEDGEMENTS

We would like to thank Marleen van der Berg, Maud van Zagten, Tijn Borm and Fleur Derks for their dedicated work in approaching families and follow-up assessments.

Conflict of interest statement.

The authors report no conflict of interest.

REFERENCES

1. Yougbare I, Lang S, Yang H, Chen P, Zhao X, Tai WS, et al. Maternal anti-platelet beta3 integrins impair angiogenesis and cause intracranial hemorrhage. *J Clin Invest*. 2015;125(4):1545-56.
2. Santoso S, Wihadmyatami H, Bakchoul T, Werth S, Al-Fakhri N, Bein G, et al. Antiendothelial alphavbeta3 Antibodies Are a Major Cause of Intracranial Bleeding in Fetal/Neonatal Alloimmune Thrombocytopenia. *Arterioscler Thromb Vasc Biol*. 2016;36(8):1517-24.
3. van Gils JM, Stutterheim J, van Duijn TJ, Zwaginga JJ, Porcelijn L, de Haas M, et al. HPA-1a alloantibodies reduce endothelial cell spreading and monolayer integrity. *Mol Immunol*. 2009;46(3):406-15.
4. Radder CM, Brand A, Kanhai HH. Will it ever be possible to balance the risk of intracranial haemorrhage in fetal or neonatal alloimmune thrombocytopenia against the risk of treatment strategies to prevent it? *Vox Sang*. 2003;84(4):318-25.
5. Winkelhorst D, Murphy MF, Greinacher A, Shehata N, Bakchoul T, Massey E, et al. Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. *Blood*. 2017;129(11):1538-47.
6. Lieberman L, Greinacher A, Murphy MF, Bussel J, Bakchoul T, Corke S, et al. Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. *Br J Haematol*. 2019;185(3):549-62.
7. Winkelhorst D, Oepkes D, Lopriore E. Fetal and neonatal alloimmune thrombocytopenia: evidence based antenatal and postnatal management strategies. *Expert Rev Hematol*. 2017;10(8):729-37.
8. Wabnitz H, Khan R, Lazarus AH. The use of IVIg in fetal and neonatal alloimmune thrombocytopenia- Principles and mechanisms. *Transfus Apher Sci*. 2020;59(1):102710.
9. Zhi H, Ahlen MT, Skogen B, Newman DK, Newman PJ. Preclinical evaluation of immunotherapeutic regimens for fetal/neonatal alloimmune thrombocytopenia. *Blood Adv*. 2021;5(18):3552-62.
10. Herrmann A, Samelson-Jones BJ, Brake S, Samelson R. IVIG-Associated Maternal Pancytopenia during Treatment for Neonatal Alloimmune Thrombocytopenia. *AJP reports*. 2017;7(3):e197-e200.
11. Rossi KQ, Lehman KJ, O'Shaughnessy RW. Effects of antepartum therapy for fetal alloimmune thrombocytopenia on maternal lifestyle. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2016;29(11):1783-8.
12. Radder CM, de Haan MJ, Brand A, Stoelhorst GM, Veen S, Kanhai HH. Follow up of children after antenatal treatment for alloimmune thrombocytopenia. *Early Hum Dev*. 2004;80(1):65-76.
13. Ward MJ, Pauliny J, Lipper EG, Bussel JB. Long-term effects of fetal and neonatal alloimmune thrombocytopenia and its antenatal treatment on the medical and developmental outcomes of affected children. *Am J Perinatol*. 2006;23(8):487-92.
14. Tiller H, Kamphuis MM, Flodmark O, Papadogiannakis N, David AL, Sainio S, et al. Fetal intracranial haemorrhages caused by fetal and neonatal alloimmune thrombocytopenia: an observational cohort study of 43 cases from an international multicentre registry. *BMJ Open*. 2013;3(3).
15. Winkelhorst D, Kamphuis MM, Steggerda SJ, Rijken M, Oepkes D, Lopriore E, et al. Perinatal Outcome and Long-Term Neurodevelopment after Intracranial Haemorrhage due to Fetal and Neonatal Alloimmune Thrombocytopenia. *Fetal Diagn Ther*. 2019;45(3):184-91.
16. Porcelijn L, Huiskes E, de Haas M. Progress and development of platelet antibody detection. *Transfus Apher Sci*. 2020;59(1):102705.
17. Paridaans NP, Kamphuis MM, Taune Wikman A, Tiblad E, Van den Akker ES, Lopriore E, et al. Low-Dose versus Standard-Dose Intravenous Immunoglobulin to Prevent Fetal Intracranial Hemorrhage in Fetal and Neonatal Alloimmune Thrombocytopenia: A Randomized Trial. *Fetal Diagn Ther*. 2015;38(2):147-53.
18. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. *J Pediatr*. 1978;92(4):529-34.
19. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. *Ann Surg*. 1978;187(1):1-7.
20. Hoftiezer L, Hof MHP, Dijks-Elzinga J, Hogeveen M, Hukkelhoven C, van Lingel RA. From population reference to national standard: new and improved birthweight charts. *Am J Obstet Gynecol*. 2019;220(4):383 e1- e17.
21. Maslowski R. De sociale staat van Nederland: 2020 2020 [cited 2021 26-11-2021]. Available from: <https://digitaal.scp.nl/ssn2020/onderwijs>.
22. Castor EDC. Castor Electronic Data Capture 2019 [27 Aug. 2019]. Available from: <https://castoredc.com>.

23. Wechsler D. WPPSI: Wechsler preschool and primary scale of intelligence. New York, N.Y. : Psychological Corporation, [1967] ©1967; 1967.
24. Wechsler D. WISC: Wechsler Intelligence Scale for Children. San Antonio, TX: Pearson plc; 1949.
25. Hadders-Algra M. Two distinct forms of minor neurological dysfunction: perspectives emerging from a review of data of the Groningen Perinatal Project. *Dev Med Child Neurol.* 2002;44(8):561-71.
26. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. *Dev Med Child Neurol.* 1997;39(4):214-23.
27. Verhulst FC, van der Ende J, Koot HM. Child Behavior Checklist (CBCL)/ 4-18 manual. Rotterdam: Afdeling Kinder- en Jeugdpsychiatrie, Sophia Kinderziekenhuis/Academisch Ziekenhuis Rotterdam/ Erasmus Universiteit Rotterdam.1996.
28. Gilijns PVL. Het CITO leerlingvolgsysteem: Met het oog op de praktijk [The CITO pupil monitoring system: focus on practice]. *Pedagogische Studiën.* 1992;86:291-6.
29. Vlug K. Because every pupil counts: the success of the pupil monitoring system in The Netherlands. *Education and Information Technologies.* 1997;2:287-306.
30. Tiller H, Husebekk A, Skogen B, Kjeldsen-Kragh J, Kjaer M. True risk of fetal/neonatal alloimmune thrombocytopenia in subsequent pregnancies: a prospective observational follow-up study. *BJOG.* 2016;123(5):738-44.
31. D'Mello RJ, Hsu CD, Chaiworapongsa P, Chaiworapongsa T. Update on the Use of Intravenous Immunoglobulin in Pregnancy. *NeoReviews.* 2021;22(1):e7-e24.

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL TABLE. Comparison of the characteristics of cases that were included to cases that were lost to follow-up

	Included cases n = 41	Lost to follow-up n = 9
HPA specificity, n (%)		
HPA-1a	33 (80)	6 (67)
HPA-5b	4 (10)	1 (11)
Other	4 (10)	2 (22)
Gestational age at delivery, median (IQR)§	37+5 (37+2 – 38+3)	38+0 (37+1 – 39+2)
First pregnancy, n (%)	0	0
Female sex, n (%)	21 (51)	6 (87)
Birthweight, gram, median (IQR)§	3210 (2838 – 3427)	3116 (2645 – 3385)
SGA, n/N (%)§	2/41 (5)	1/7 (14)
Platelet count nadir, median (IQR)§	65 (20 – 164)	88 (50 – 247)
Skin bleeding, n/N (%)§	10/41 (24)	0/7 (0)
Severe ICH, n (%)	2/41 (5)	0
Postnatal therapy, n (%)§	14/41 (34)	1/7 (14)

Characteristics of the included cases were compared to the cases that were lost to follow-up.

Analysis was performed using the Mann Whitney U test (gestational age, birthweight and platelet count) or with the Fisher's Exact Test (categorical variables). No statistically significant differences ($P < 0.05$) were found.

§ Data available for 7/9 (78%) of the cases that were lost to follow-up.

Abbreviations: HPA, human platelet antigen; SGA, small for gestational age; ICH, intracranial hemorrhage.

